Recent studies have shown an increased incidence of renal replacement therapy after the use of Hydroxyethylstarchs (HES) in patients admitted in the intensive care unit. However, studies showing detrimental effects of HES have been conducted in mostly non-surgical subjects. There are very few studies analyzing the effects of HES on renal function after cardiac surgery, a population already at risk of renal dysfunction.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,564
Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
Renal dysfunction based on RIFLE (Risk; Injury; Failure; Loss; End-stage) criteria.
Time frame: Up to 45 days
Mortality
Time frame: Up to 45 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.